Background : Left ventricular (LV) hypertrophy, a key process in human cardiac disease,
results from cellular (hypertrophy) and extracellular matrix expansion (interstitial fibrosis). …

Objectives : This study sought to explore the Fabry myocardium in relation to storage, age,
sex, structure, function, electrocardiogram changes, blood biomarkers, and inflammation/…

Fabry disease (FD) is an X-linked lysosomal storage disorder caused by deficiency of α-galactosidase
A enzyme. Cardiovascular (CV) disease is a common cause of mortality in FD, in …

Objectives : The goal of this study was to explore sex differences in myocardial remodeling
in aortic stenosis (AS) by using echocardiography, cardiac magnetic resonance (CMR), and …

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in a-galactosidase
A. Sphingolipid accumulates in organs including the heart, causing left …

Aims Cardiac involvement in Fabry disease (FD) occurs prior to left ventricular hypertrophy (LVH)
and is characterized by low myocardial native T1 with sphingolipid storage reflected by …

Purpose To show that the use of a multi‐velocity encoding (VENC) 4D‐flow approach offers
significant improvements in the characterization of complex flow in the aorta. Four‐…

Background: Fabry disease (FD) is a rare and treatable X-linked lysosomal storage disorder.
Cardiac involvement determines outcomes; therefore, detecting early changes is important. …

Background: Cardiac response to enzyme replacement therapy (ERT) in Fabry disease is
typically assessed by measuring left ventricular mass index using echocardiography or …

Background Sphingolipid deposition in Fabry disease causes left ventricular (LV) hypertrophy,
of which the accurate assessment is essential. Cardiovascular magnetic resonance (CMR…